(RTTNews) - GSK plc (GSK, GSK.L) announced that China's National Medical Products Administration has approved Exdensur or depemokimab as add-on maintenance treatment of severe asthma characterised by an eosinophilic phenotype in adult and paediatric patients aged 12 years and older. The approval is based on data from the SWIFT-1 and SWIFT-2 phase III trials.
Kaivan Khavandi, SVP, Global Head, Respiratory, Immunology & Inflammation R&D, GSK, said: "With Exdensur now approved in several major markets, we are focused on transforming the treatment paradigm in severe asthma."
At last close, GSK shares were trading at 2,049.00 pence.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
